肿瘤细胞治疗研究
英文原题：HER2(+) advanced gastric cancer: Current state and opportunities (Review).
人表皮生长因子受体2（HER2）阳性胃癌（GC）是GC的一种独特亚型，占所有GC病例的10-20%。
人表皮生长因子受体2（HER2）阳性胃癌（GC）是GC的一种独特亚型，占所有GC病例的10‑20%。尽管抗HER2单克隆抗体曲妥珠单抗的开发显著提高了HER2阳性晚期GC（AGC）患者的缓解率和预后，但耐药性仍然是一个相当大的挑战。因此，动态监测HER2表达水平有助于识别可能从靶向治疗中获益的患者。除曲妥珠单抗外，DS‑8201和RC48已应用于HER2阳性AGC的治疗，多种新型抗HER2疗法正在进行临床前/临床试验。目前，抗HER2药物联合免疫治疗被用作该疾病亚型的一线治疗。CAR-T 细胞免疫治疗和癌症疫苗等有前景的新方法也正在研究其改善临床结局的潜力。本综述通过总结HER2阳性AGC靶向治疗药物及联合治疗的研究进展，为抗HER2治疗的未来应用提供了新的见解。
Human epidermal growth factor receptor 2 (HER2) + gastric cancer (GC) is a distinct subtype of GC, accounting for 10‑20% of all cases of GC. Although the development of the anti‑HER2 monoclonal antibody trastuzumab has markedly improved response rates and prognosis of patients with HER2 + advanced GC (AGC), drug resistance remains a considerable challenge. Therefore, dynamic monitoring of HER2 expression levels can facilitate the identification of patients who may benefit from targeted therapy. Besides trastuzumab, DS‑8201 and RC48 have been applied in the treatment of HER2 + AGC, and several novel anti‑HER2 therapies are undergoing preclinical/clinical trials. At present, combination immunotherapy with anti‑HER2 agents is used as the first‑line treatment of this disease subtype. New promising approaches such as chimeric antigen receptor T‑cell immunotherapy and cancer vaccines are also being investigated for their potential to improve clinical outcomes. The current review provides new insights that will guide the future application of anti‑HER2 therapy by summarizing research progress on targeted therapy drugs for HER2 + AGC and combination treatments.
MEMBER ACCOUNT
登录成功会直接打开下一页。
